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Quality-of-life assessments in children with asthma have enabled
us to understand the significant impact of asthma on their lives. In
addition, and possibly more importantly, they enable us to
evaluate the therapy we use in asthmatic children. Such
assessments indicate that we, as clinicians, are not doing as well as
we would hope in the control of asthma using current therapeutic
strategies.
All treatment interventions in asthma management have two
objectives. Patients want improvement in their quality of life
(absence of morbidity and mortality), and the funders want cost-
effective care. These objectives are reflected in the goals of asthma
management in all local and international guidelines (Table I).
From time to time we need to check on how well we are doing
in achieving these goals. Unfortunately such analysis is seldom
performed and the studies conducted reveal a pessimistic picture.2,3
Management of the young (preschool) asthmatic needs critical
evaluation as the evidence presented suggests that disease control
is especially poor in this subpopulation.
Although most paediatric asthma management guidelines
recognise the special nature of asthma in young children, they fail
to acknowledge the limitations of current therapies in controlling
inflammation in this age group. Recent studies have revealed that
asthma prevalence is on the increase,4 and that the prevalence in
South Africa is significant.5,6 This is one of the commonest chronic
conditions in childhood and requires our full attention. In addition
to this background picture, there is evidence that the prevalence is
increasing at a greater rate in young children.7 There is also
evidence that 50 - 80% of asthmatics develop the disease before the
age of 5 years.8
We know today that the pathology of asthma is similar, if not
identical, in young children and adults;9 because of this, it has been
stressed that effective therapy necessitates anti-inflammatory
drugs. How well are we doing then in controlling this disease?  
At the most basic level of assessment, namely mortality,
evidence of success has until recently been very disappointing.
Mortality from asthma has been increasing and very significantly
so in children.10 However, studies of quality of life show a
disappointing outcome in morbidity control. Remarkably, different
studies reveal similar results. On average one-third of children are
waking up at night at least once a week due to asthma2,3 and
missing school at an alarmingly significant rate.3,11
In view of this lack of success in asthma control it is not
surprising that the disease is resulting in spiralling costs. In a
recent analysis of total inpatient costs (as a marker of uncontrolled
asthma and exacerbations) in Scandinavia, the young asthmatic
was found to be responsible for a disproportionately high
percentage of this bill (Fig. 1).12 This evidence must suggest a
failure of current preventive therapeutic approaches in this age
group.
For a treatment strategy to be effective, there must be synergy
between efficacy of a product and adherence to that product in
real, day-to-day life. Although clinical trials suggest efficacy of
many products, many factors influence adherence (Fig. 2). There
are a number of limitations to inhaled anti-inflammatory therapy
in asthma management. In general, and at best, only 20 - 25% of
the delivered dose reaches the lower airway.13 In reality, however,
compliance with inhaled therapy is poor14 (Fig. 3), even in South
Africa.  For the majority of older children and adults the inhaled
route is the preferred delivery route and patients need to be
educated to use their therapy correctly and regularly. It is for this
reason that most countries have asthma education bodies. 
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Table I.  The goal of asthma management is that the asthmatic is
able to lead a normal and physically active life 
For a normal life the aim is to:
• Be completely free of any symptoms, i.e. cough, wheeze and
breathlessness   
• Attend school regularly and participate fully in all school
activities, including sport  
• Have restful sleep free from nighttime cough and/or
wheeze  
• Minimise the number of asthma attacks
• Avoid hospital admissions
• Grow normally
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However, in young children quality-of-life assessments and
spiralling inpatient costs testify to failure of attempts to implement
therapy via the inhaled route. Most clinicians working with
parents of young asthmatics can relate stories of unhappy attempts
to get toddlers to use spacer devices. Our endpoint assessments
suggest that this is the rule rather than the exception.
Lastly it should be noted that most of the inhaled therapies
recommended in guidelines are in fact not registered for use in
young children (Fig. 4).  Although this lack of registration does not
attest to lack of efficacy or safety, it does suggest the difficulty in
assessing these endpoints in this age group.
Where to then, in this worrying situation?  Recently an oral
anti-inflammatory drug was registered for use in 2 - 5-year-old
asthmatics. Montelukast (Singulair) is a leukotriene receptor
antagonist now licensed for use in young asthmatics. In clinical
trials this drug has shown dramatic results in controlling the
symptoms and disease that is asthma.15 It is available as a
pleasant-tasting chewable tablet for once-a-day administration and
has no significant safety issues. A safe and effective oral anti-
inflammatory preparation for controlling asthma in the young
child is now available. The advantages of this preparation are
obvious (Table II), but in the face of the unhappy picture of asthma
control, the preparation may offer a truly unique breakthrough in
pre-school asthma.
Despite this optimism, montelukast should be used in a
responsible and controlled way. This drug is advocated as
monotherapy for mild to moderate asthma in the pre-school age
group only. Standard inhaled therapy is still recommended for
older children and for failure to control all symptoms of asthma in
the young age group.
In most young children, asthma control is determined by
symptom control, as most patients will not be able to perform lung
function testing. The availability of montelukast will, it is hoped,
lead to success in quality-of-life and cost-effectiveness parameters,
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Fig. 2. Determinants of effectiveness of drug therapy.
Table II.  Advantages of monteleucast
• Oral therapy (compliance)
• Single daily dose
• Safe therapy (not a steroid)
• No food/drug interactions
• Registered for young children
• Anti-inflammatory
I am surprised you are reading this sentence. I would have
expected the average doctor’s eyes to have glazed over on reading
the title of this article and for him or her to have turned over the
page in search of the locums-available- in-Australia column.  As
you are still with me let’s have a shot at defining what it is.
NLP (yes, it gets shortened into one of those ubiquitous
acronyms) is about communication.  It is about how we take in
and process information from the patient and how we interpret it
through our internal filters (that’s the ‘neuro’ part) and it is about
how we use language, how we label things and how we talk
(that’s the ‘linguistic’ part). We use all of this, and more, to improve
our rapport with the patient and collect feedback from the patient
so that we can flexibly adjust our actions, words, non-verbal
gestures and approaches to the patient in order to achieve our
particular goal, which in most cases is helping the patient change
his or her health behaviours (that, in one long sentence, is the
‘programming’ part).
Now if you think neurolinguistic programming is a mouthful,
hold on for the jargon that goes with it. For example, there is
modelling, consulting flow states, meta-programmes, meta-
models, break states, pacing, chunking and verbal reframing skills.
These are all some of the skills that doctors who are good
communicators have acquired over the years and that have not
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but this is a long-term goal. In the short term monteleucast offers
the opportunity to refocus on the goals of asthma management as
set out by the South African Childhood Asthma Working Group
(SACAWG) (Table I).
Montelukast is not a panacea for asthma. Recommendation for
its use, as a new therapeutic strategy, carries a huge responsibility.
In order to meet this challenge certain guidelines are suggested for
determining the ideal patient and for safeguarding both the patient
and the reputation of the product (Table III).
We feel that the time is right for a shift in our recommendations
for the management of young asthmatics and hope that this
treatment approach will be adopted in future guidelines, but more
importantly, improve the quality of life of our patients and reduce
the enormous financial burden resulting from poor control of this
common illness in young children.   
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Table III. Indications for montelukast
In a  child 2 - 5 years of age with asthma:
1. Diagnosis:  Chronic cough or wheeze responsive to a
bronchodilator or 7 - 10-day course of oral steroids
(prednisolone 1 mg/kg/day)
‘The modified bronchodilator response test’: Document
symptoms and signs of asthma (e.g. audible wheeze,
hyperinflated chest, prolonged expiration) and then give two
puffs of a bronchodilator/nebuliser.  Assess the response
objectively at 10 - 15 minutes. 
2. Four-week trial of montelukast
3. Response to montelukast as indicated by a significant
reduction in symptoms or use of bronchodilators
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